Crohn's Diseases
6
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (6)
Cardiovascular Risk in Patients With IBD
Assessment on the Deep Remission Rate and Its Influencing Factors of Individualized Ustekinumab Therapy in Patients With Crohn's Disease
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease
To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related Stricture
Washed Microbiota Transplantation Improves Nutritional Status of Patients With Crohn's Disease